Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GLSI NASDAQ:OLMA NASDAQ:ORIC NASDAQ:PURR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGLSIGreenwich LifeSciences$14.78+5.1%$23.13$7.78▼$34.10$216.75M1.4249,078 shs192,205 shsOLMAOlema Pharmaceuticals$11.68+2.9%$11.78$4.40▼$36.26$1.02B21.49 million shs194,865 shsORICOric Pharmaceuticals$10.95+5.1%$9.17$7.23▼$14.93$1.13B1.021.78 million shs753,457 shsPURRHyperliquid Strategies$6.99-0.9%$8.27$3.01▼$11.62$1.02B1.668.65 million shs4.45 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGLSIGreenwich LifeSciences-13.79%-24.23%-39.82%-38.59%+21.40%OLMAOlema Pharmaceuticals-1.05%-4.22%+19.35%-31.75%+157.37%ORICOric Pharmaceuticals-2.89%-0.38%+22.73%-1.98%-5.36%PURRHyperliquid Strategies+5.54%-1.54%-24.03%+25.00%+704,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGLSIGreenwich LifeSciences$14.78+5.1%$23.13$7.78▼$34.10$216.75M1.4249,078 shs192,205 shsOLMAOlema Pharmaceuticals$11.68+2.9%$11.78$4.40▼$36.26$1.02B21.49 million shs194,865 shsORICOric Pharmaceuticals$10.95+5.1%$9.17$7.23▼$14.93$1.13B1.021.78 million shs753,457 shsPURRHyperliquid Strategies$6.99-0.9%$8.27$3.01▼$11.62$1.02B1.668.65 million shs4.45 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGLSIGreenwich LifeSciences-13.79%-24.23%-39.82%-38.59%+21.40%OLMAOlema Pharmaceuticals-1.05%-4.22%+19.35%-31.75%+157.37%ORICOric Pharmaceuticals-2.89%-0.38%+22.73%-1.98%-5.36%PURRHyperliquid Strategies+5.54%-1.54%-24.03%+25.00%+704,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGLSIGreenwich LifeSciences 2.33Hold$57.00285.55% UpsideOLMAOlema Pharmaceuticals 2.71Moderate Buy$44.10277.54% UpsideORICOric Pharmaceuticals 2.75Moderate Buy$19.2775.94% UpsidePURRHyperliquid Strategies 2.50Moderate Buy$12.7282.06% UpsideCurrent Analyst Ratings BreakdownLatest GLSI, ORIC, PURR, and OLMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/21/2026GLSIGreenwich LifeSciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$50.00 ➝ $69.007/17/2026OLMAOlema Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026ORICOric Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/1/2026PURRHyperliquid Strategies Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$8.00 ➝ $18.406/12/2026ORICOric Pharmaceuticals Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$14.006/12/2026PURRHyperliquid Strategies Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.756/8/2026ORICOric Pharmaceuticals BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/8/2026ORICOric Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.006/3/2026PURRHyperliquid Strategies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)5/22/2026ORICOric Pharmaceuticals Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/22/2026OLMAOlema Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 7/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGLSIGreenwich LifeSciencesN/AN/AN/AN/A$0.03 per shareN/AOLMAOlema PharmaceuticalsN/AN/AN/AN/A$5.88 per shareN/AORICOric PharmaceuticalsN/AN/AN/AN/A$3.90 per shareN/APURRHyperliquid Strategies$1M1,008.98N/AN/A$1.52 per share4.60Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGLSIGreenwich LifeSciences-$19.36M-$1.57N/AN/AN/AN/A-941.15%-368.53%8/13/2026 (Estimated)OLMAOlema Pharmaceuticals-$162.45M-$2.02N/AN/AN/AN/A-46.00%-41.22%8/10/2026 (Estimated)ORICOric Pharmaceuticals-$129.47M-$1.44N/AN/AN/AN/A-35.33%-33.31%8/11/2026 (Estimated)PURRHyperliquid Strategies-$16.01M-$7.37N/AN/AN/AN/A-56.04%-52.22%N/ALatest GLSI, ORIC, PURR, and OLMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2026Q2 2026GLSIGreenwich LifeSciences-$0.34N/AN/AN/AN/AN/A8/11/2026Q2 2026ORICOric Pharmaceuticals-$0.36N/AN/AN/AN/AN/A8/10/2026Q2 2026OLMAOlema Pharmaceuticals-$0.53N/AN/AN/AN/AN/A5/12/2026Q1 2026OLMAOlema Pharmaceuticals-$0.52-$0.52N/A-$0.52N/AN/A5/7/2026Q3 2026PURRHyperliquid StrategiesN/A$1.01N/A$1.01N/A$2.63 million5/4/2026Q1 2026ORICOric Pharmaceuticals-$0.31-$0.34-$0.03-$0.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGLSIGreenwich LifeSciencesN/AN/AN/AN/AN/AOLMAOlema PharmaceuticalsN/AN/AN/AN/AN/AORICOric PharmaceuticalsN/AN/AN/AN/AN/APURRHyperliquid StrategiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGLSIGreenwich LifeSciencesN/A2.012.01OLMAOlema Pharmaceuticals0.0110.8810.88ORICOric PharmaceuticalsN/A16.3316.33PURRHyperliquid StrategiesN/A18.2318.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGLSIGreenwich LifeSciences4.16%OLMAOlema Pharmaceuticals91.78%ORICOric Pharmaceuticals95.05%PURRHyperliquid Strategies9.45%Insider OwnershipCompanyInsider OwnershipGLSIGreenwich LifeSciences51.47%OLMAOlema Pharmaceuticals12.56%ORICOric Pharmaceuticals5.70%PURRHyperliquid Strategies8.48%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGLSIGreenwich LifeSciences314.68 million7.12 millionNot OptionableOLMAOlema Pharmaceuticals7087.35 million76.38 millionOptionableORICOric Pharmaceuticals80103.52 million97.62 millionOptionablePURRHyperliquid StrategiesN/A144.45 million132.20 millionN/AGLSI, ORIC, PURR, and OLMA HeadlinesRecent News About These CompaniesHyperliquid Strategies Inc (PURR) Slides 3.91%: Testing Key Support Levels Amid Bearish Pressure - Dealer GammaJuly 13, 2026 | donanimhaber.comDHyperliquid Strategies (NASDAQ:PURR) Shares Gap Up - Time to Buy?July 10, 2026 | marketbeat.comDefiance Launches PUR: The First 2X Long PURR ETFJuly 8, 2026 | globenewswire.comWhy Money Is Leaving Bitcoin for HyperliquidJuly 3, 2026 | aol.comAHyperliquid Strategies Inc Added to the Russell 3000, Russell 2000 and S&P Global BMI IndicesJune 29, 2026 | prnewswire.comHyperliquid Strategies Enhances Executive Compensation and Leadership StructureJune 26, 2026 | tipranks.comPanther Minerals Announces Brokered Private Placement of up to $3,000,000June 16, 2026 | accessnewswire.comAHyperliquid Strategies shares jump as HYPE token strength and late-June index reconstitution fuel buyingJune 16, 2026 | quiverquant.comQHyperliquid Strategies Stock Is Surging Tuesday: What's Driving The Action?June 16, 2026 | benzinga.comWhy Is Hyperliquid Strategies Stock Gaining Monday?June 15, 2026 | benzinga.comPanther Minerals Announces Appointment of Harrison Glancy to Board of DirectorsJune 10, 2026 | accessnewswire.comAHyperliquid Strategies (PURR) Is Down 14.6% After Gamma Squeeze Speculation and Index Inclusion Buzz – What's ChangedJune 7, 2026 | finance.yahoo.comComparing HYPE & PURR: The Most Stock-Like Crypto PlayJune 5, 2026 | seekingalpha.comArthur Hayes: My $100,000 Against Yours That SOL Will Not Outperform The Hottest Coin In The MarketJune 2, 2026 | benzinga.comPURR Stock On Track For Record High After Hyperliquid Flips Dogecoin To Enter Crypto Top 10June 1, 2026 | finance.yahoo.comHyperliquid Is 'Bigger Than Nasdaq,' Says ICE CEO — HYPE Eyes New Record High, While ETFs Top $100MMay 30, 2026 | finance.yahoo.comHyperliquid Strategies (PURR) jumps as Russell Microcap inclusion chatter lifts demandMay 29, 2026 | quiverquant.comQWhy Hyperliquid Strategies Inc.’s (PURR) Stock Is Up 12.26%May 28, 2026 | aaii.comAGoldman Sachs Sells XRP and SOL ETF, Pivots to Hyperliquid in Q1 2026May 22, 2026 | memeburn.comMHyperliquid token surges toward all-time high after spot ETF inflows hit record – 'Everything is down lately except HYPE,' says analystMay 22, 2026 | msn.comThe Token Takeover: SEC Triggers Market Quake (PURR)...May 21, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSK Hynix’s Nasdaq Listing Could Reset the AI Memory TradeBy Thomas Hughes | July 7, 20265 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026Meta's Internal Turmoil: Morale Nears 20-Year Low at the Wrong TimeBy Leo Miller | June 24, 2026SpaceX’s Historic IPO Has Already Sparked a 2X ETF FrenzyBy Ryan Hasson | June 22, 2026PepsiCo’s Dividend Could Turn Patience Into Real ProfitBy Thomas Hughes | July 10, 2026GLSI, ORIC, PURR, and OLMA Company DescriptionsGreenwich LifeSciences NASDAQ:GLSI$14.78 +0.71 (+5.07%) As of 01:37 PM Eastern This is a fair market value price provided by Massive. Learn more.Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.Olema Pharmaceuticals NASDAQ:OLMA$11.68 +0.33 (+2.92%) As of 01:36 PM Eastern This is a fair market value price provided by Massive. Learn more.Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.Oric Pharmaceuticals NASDAQ:ORIC$10.95 +0.53 (+5.12%) As of 01:37 PM Eastern This is a fair market value price provided by Massive. Learn more.ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.Hyperliquid Strategies NASDAQ:PURR$6.98 -0.07 (-0.92%) As of 01:37 PM Eastern This is a fair market value price provided by Massive. Learn more.Hyperliquid Strategies Inc is a digital asset treasury company whose primary focus is to maximize shareholder value through accumulating HYPE, the native token of Hyperliquid, a high-performance blockchain custom-built to house all of finance. Hyperliquid Strategies Inc, formerly known as Sonnet BioTherapeutics Holdings Inc., is based in NEW YORK. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Is Planning a New AI Chip. Here's Why It Matters Ahead of Earnings Industrial and Utility Giants Boost Dividends as Data Center Tailwinds Build IREN’s $2.8 Billion AI Contract Haul Changes the Stock’s Story 2 ETFs to Access the World's Best-Performing Stock Markets In 2026 Microsoft's AI Bet Could Rewrite AMD's Growth Story Buy, Hold, or Wait: 3 Small-Cap Stocks Telling Different Stories The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino's Stock Serving Up a Buying Opportunity? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
